ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0454

Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR

Rachael Flood1, Richard Conway2, David Kane1 and Ronan Mullan1, 1Tallaght University Hospital, Dublin, Ireland, 2St James's Hospital, Dublin, Ireland

Meeting: ACR Convergence 2020

Keywords: Biologicals, COVID-19, registry

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Friday, November 6, 2020

Session Title: Infection-related Rheumatic Disease (0454–0458)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Anticytokine biological disease modifying anti-rheumatic drugs (bDMARD), which are widely prescribed  for Inflammatory Rheumatological Diseases (IRD) are currently undergoing clinical trials for the treatment of Covid-19. Despite indicators that bDMARDs ought to reduce adverse outcomes through inhibition of hyperinflammatory cytokine storm events, only one global registry of 600 Covid-19 IRD patients has indicated that pre-treatment with the tumour necrosis factor inhibitor class of bDMARD protects against hospitalisation. Furthermore global registry reports of admission rates of 46% in IRD are at variance with lower rates recently published in the NEJM, suggesting a potential reporting bias in registry data towards hospitalised patients, including those who may only become infected during hospitalisation for an unrelated condition.

Methods: To eliminate reporting bias we contacted 7,500 patients comprising 4,524 with IRDs and 2,976 with non-inflammatory disease (nIRDs) attending Trinity College Dublin aligned academic Rheumatology centres,   collecting data up to the end of the 1st pandemic wave in Ireland on 03rd June 2020. Cross-referencing with test-centre positive polymerase chain reaction (PCR) results and mortality data was performed to ensure complete collation of cases. 

Results: We identified 77 cases of PCR or physician diagnosed COVID-19, of whom 68 were community acquired (supplementary table 1) and 9 were hospital acquired. No differences were seen in cumulative incidence/100,000 of COVID-19 between IRD (884), non-inflammatory rheumatic disorders (nIRD, 940), or incidence rates for metropolitan Dublin (887). In subgroup analysis of community acquired infection, hospitalisation was statistically less likely in patients receiving long-term anticytokine biological therapies (P< 0.05). This significance was lost when hospital acquired cases were included. In further analysis of the 40 IRD and 28 nIRD community acquired cases, hospitalisation was more likely to occur in those receiving glucocorticosteroids (p< 0.01) or those diagnosed with type 2 diabetes (p< 0.05). Lower hospitalisation rates for community acquired Covid-19 in IRD (15%), equivalent to national figures (13%) were observed.

Conclusion: Unintentional bias in reporting hospitalised COVID-19 cases to IRD registries and the inclusion of hospital acquired cases during data analysis, may lead to spurious overestimates of overall morbidity while masking critically important information on the role of anticytokine therapies in preventing hospitalisation. Although our dataset is small, these results suggest a much more powerful role for anticytokine therapies in treating COVID-19 than existing published registry data indicate. Further analysis using existing datasets on community acquired cases, are likely to more rapidly identify existing drugs to treat COVID-19, which are urgently required to improve health outcomes.


Disclosure: R. Flood, None; R. Conway, None; D. Kane, None; R. Mullan, None.

To cite this abstract in AMA style:

Flood R, Conway R, Kane D, Mullan R. Anticytokine Therapies for Inflammatory Rheumatic Disease (IRD) Are Associated with Reduced Hospitalisation Following Community COVID-19 Infection; Results of the Trinity Rheumatology and Covid-19 Registry – TRACR [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anticytokine-therapies-for-inflammatory-rheumatic-disease-ird-are-associated-with-reduced-hospitalisation-following-community-covid-19-infection-results-of-the-trinity-rheumatology-and-covid-19-reg/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anticytokine-therapies-for-inflammatory-rheumatic-disease-ird-are-associated-with-reduced-hospitalisation-following-community-covid-19-infection-results-of-the-trinity-rheumatology-and-covid-19-reg/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.